The forecast for the Genito-Urinary System and Sex Hormones sales in the UK shows a declining trend from 2024 to 2028. The market value is expected to decrease from $918.97 million in 2024 to $882.85 million in 2028, marking a steady year-on-year decline. In 2023, the sales stood at a value not specified here, but this downward trajectory suggests a negative CAGR for the period from 2024 to 2028, indicating an average annual decrease in market value.

Future trends to watch for include:

Potential changes in healthcare policies or regulations that could impact the market.
Development of new treatments or drugs in the genito-urinary and sex hormones sector which may alter market dynamics.
Shifts in demographic patterns like aging populations that could drive demand.
Technological advancements and increased competition from generic drugs that could influence pricing and sales volumes.
Economic conditions and spending on healthcare priorities may affect market performance.